A Look at Biosimilar Education Among European Oncologists

The cost of cancer care is on the rise worldwide, and biosimilars present one option for bringing down costs. However, those savings depend on adoption and use of biosimilars, and hesitancy to use these agents on the part of prescribers has been well documented. One newly published study reported on a survey conducted among European Society for Medical Oncology (ESMO) members and attendees of the 2017 ESMO Congress in Madrid, Spain, concerning biosimilars.

This week, we’re speaking with the study’s lead author, Rosa Giuliani, MD. She’s a medical oncologist at The Christie Hospital, Manchester, United Kingdom, and Chair of the ESMO Global Policy Committee.